CN103328466B - Hcv ns3蛋白酶抑制剂 - Google Patents
Hcv ns3蛋白酶抑制剂 Download PDFInfo
- Publication number
- CN103328466B CN103328466B CN201180063866.1A CN201180063866A CN103328466B CN 103328466 B CN103328466 B CN 103328466B CN 201180063866 A CN201180063866 A CN 201180063866A CN 103328466 B CN103328466 B CN 103328466B
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- hcv
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 112
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 15
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 230000001629 suppression Effects 0.000 claims description 9
- 239000011737 fluorine Substances 0.000 claims description 8
- 125000001769 aryl amino group Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 108010022999 Serine Proteases Proteins 0.000 claims description 6
- 102000012479 Serine Proteases Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 125000000468 ketone group Chemical group 0.000 claims description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 27
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- -1 R " XYR " in Chemical class 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 29
- 241000711549 Hepacivirus C Species 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 19
- 239000002585 base Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 125000000217 alkyl group Chemical group 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000000758 substrate Substances 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 8
- 108010088842 Fibrinolysin Proteins 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108090000613 Cathepsin S Proteins 0.000 description 5
- 102100035654 Cathepsin S Human genes 0.000 description 5
- 108020005196 Mitochondrial DNA Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229940001501 fibrinolysin Drugs 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000003470 mitochondria Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001311 chemical methods and process Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 150000001989 diazonium salts Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004660 morphological change Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 108700022487 rRNA Genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940122604 HCV protease inhibitor Drugs 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 102100033174 Neutrophil elastase Human genes 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940122791 Plasmin inhibitor Drugs 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000872198 Serjania polyphylla Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000013096 assay test Methods 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000002247 constant time method Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001867 inorganic solvent Inorganic materials 0.000 description 2
- 239000003049 inorganic solvent Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 239000002806 plasmin inhibitor Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000012622 synthetic inhibitor Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 108091064702 1 family Proteins 0.000 description 1
- 150000005070 1,2,3-oxadiazoles Chemical class 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- CUJPFPXNDSIBPG-UHFFFAOYSA-N 1,3-propanediyl Chemical group [CH2]C[CH2] CUJPFPXNDSIBPG-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- VUFVGYBIFMCJPB-UHFFFAOYSA-N 1-iodopyrimidine-2,4-dione Chemical compound IN1C=CC(=O)NC1=O VUFVGYBIFMCJPB-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YFVRIXYUQCYRAF-UHFFFAOYSA-N 2-ethenylpiperazine Chemical compound C=CC1CNCCN1 YFVRIXYUQCYRAF-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- NPYPQKXJJZZSAX-UHFFFAOYSA-N 5-benzylpyrimidine Chemical class C=1N=CN=CC=1CC1=CC=CC=C1 NPYPQKXJJZZSAX-UHFFFAOYSA-N 0.000 description 1
- PVRBGBGMDLPYKG-UHFFFAOYSA-N 6-benzyl-7h-purine Chemical compound N=1C=NC=2N=CNC=2C=1CC1=CC=CC=C1 PVRBGBGMDLPYKG-UHFFFAOYSA-N 0.000 description 1
- DBCMWACNZJYUHS-UHFFFAOYSA-N 6-ethenyl-7h-purine Chemical compound C=CC1=NC=NC2=C1NC=N2 DBCMWACNZJYUHS-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101150086475 COXII gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- SLFCPDJRSLSJKL-UHFFFAOYSA-N [1-(difluoromethoxy)-2,2,2-trifluoro-1-(trifluoromethoxy)ethyl] hypofluorite Chemical compound FC(OC(C(F)(F)F)(OF)OC(F)F)(F)F SLFCPDJRSLSJKL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 108010023472 cytochrome C oxidase subunit II Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004983 dialkoxyalkyl group Chemical group 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229950008802 fialuridine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- FWLKYEAOOIPJRL-UHFFFAOYSA-N prop-1-yn-1-ol Chemical compound CC#CO FWLKYEAOOIPJRL-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- HBCQSNAFLVXVAY-UHFFFAOYSA-N pyrimidine-2-thiol Chemical compound SC1=NC=CC=N1 HBCQSNAFLVXVAY-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及用于在人类患者或其它动物宿主内治疗或预防病毒感染(特别是HCV)的化合物、组合物和方法。
Description
技术领域
本发明涉及作为丙型肝炎病毒(HCV)NS3蛋白酶的抑制剂有用的化合物方法和组合物,所述化合物的合成,和所述化合物用于治疗HCV感染和或降低HCV感染的可能性或症状的严重性的用途。
本申请要求2010年11月1日申请的美国临时申请第61/408,989号的优先权。
背景技术
丙型肝炎病毒(HCV)在全世界范围内已感染超过180,000,000人。估计每年有三百万至四百万人新感染,他们中的70%将发展成慢性肝炎。HCV要为所有肝癌病例的50-76%以及发达世界所有肝脏移植的三分之二负责。标准疗法(聚乙二醇干扰素α加利巴韦林)仅仅在50-60%的患者中是有效的;然而,对它的有效性没有很好的了解并且它与显著的副作用有关。因此,迫切需要新的药物以治疗和/或治愈HCV(1:ChenKX,NjorogeFG.AreviewofHCVproteaseinhibitors.CurrOpinInvestigDrugs.20098,821-37;2:GargG,KarP.ManagementofHCVinfection:currentissuesandfutureoptions.TropGastroenterol.200930,11-8;3:PereiraAA,JacobsonIM.NewandexperimentaltherapiesforHCV.NatRevGastroenterolHepatol.20097,403-11)。
HCV基因组包含被包封在核衣壳和脂质囊膜中的正链RNA并且由9.6kb核糖核苷酸组成,其编码了约3000个氨基酸的大的多肽(Dymock等,AntiviralChemistry&Chemotherapy2000,11,79)。成熟后,该多肽被切割为至少10个蛋白质。位于NS3蛋白质的N末端结构域的NS3丝氨酸蛋白酶介导了随后在多蛋白中的下游的所有切割事件。由于其作用,所述NS3丝氨酸蛋白酶是一种理想的药物靶标并且在先研究已显示,六肽以及三肽显示出不同程度的抑制性,如在美国专利申请US2005/0020503、US2004/0229818和US2004/00229776中所讨论的。显示抗HCV活性的六环化合物也已在国际专利申请第W020061119061、W02007/015855和W02007/016441号(都是Merck&Co公司)中被公开
用于繁殖HCV的方便的细胞培养模式的缺乏已长时间妨碍发现选择性抑制HCV复制的新的抗病毒策略。随着在1999年复制子***的确立(Bartenschlager,R.,Nat.Rev.DrugDiscov.2002,1,911-916和Bartenschlager,R.,J.Hepatol.2005,43,210-216)和在2005年随着健壮的HCV细胞培养模式的发展(Wakita,T.,等,Nat.Med.2005,11,791-6;Zhong,J.,等,Proc.Natl.Acad.Sci.U.S.A.2005,102,9294-9;Lindenbach,B.D.,等,Science2005,309,623-6),该障碍已被首先克服。
提供新的抗病毒或化学疗法药剂、包括这些药剂的组合物以及使用这些药剂治疗的方法,特别是要治疗耐药的或突变病毒,是有利的。本发明提供了这样的药剂、组合物和方法。
发明概述
本发明提供了用于在宿主中治疗或预防HCV感染的化合物、方法和组合物。所述化合物具有以下通式:
其中R、J和J1如下文所定义。
所述方法包含施用在治疗上或预防上有效量的至少一种如本文描述的化合物以治疗或预防感染,或者施用足够的量以降低HCV感染的生物活性。所述药物组合物包括与药学上可接受的载体或辅料结合的一种或多种在本文中描述的化合物,用于治疗患有HCV的宿主。所述制剂可进一步包括至少一种其它的治疗剂。此外,本发明包括用于制备所述化合物的工艺。
丙型肝炎复制子需要病毒解旋酶、蛋白酶和聚合酶按顺序起作用以使复制子的复制发生。所述复制子可用于大通量测定中,其评估待筛选活性的化合物是否抑制HCV解旋酶、蛋白酶和/或聚合酶起作用的能力,如通过抑制复制子的复制所证实的。
详细描述
本文中描述的化合物显示抗HCV的抑制活性。因此,所述化合物可用于治疗或预防宿主中的病毒感染,或降低病毒的生物活性。所述宿主可以为HCV感染的哺乳动物,并且特别是人类。所述方法包含施用有效量的一种或多种本文描述的化合物。
还公开了包括与药学上可接受的载体或辅料结合的一种或多种本文描述的化合物的药物制剂。在一个实施方案中,所述制剂包括至少一种本文描述的化合物和至少一种另外的治疗剂。
参照以下定义将更好地理解本发明:
I.定义
术语“独立地”在本文中使用以表明独立应用的变量从应用至应用独立地变化。因此,在化合物例如R”XYR”中,其中R”“独立地”为“碳或氮”,两个R”都可以为碳,两个R”都可以为氮,或者一个R”可以为碳并且另一个R”为氮。
如本文中所使用的,术语“对映异构纯”指包含至少大约95%,并且,优选大约97%、98%、99%或100%的该化合物的单一对映体的化合物组合物。
如本文中所使用的,术语“基本不含”或“基本不存在”指包括至少85-90%重量计,优选95-98%重量计,并且更优选99-100%重量计的该化合物的指定对映体的化合物组合物。在优选实施方案中,本文描述的化合物基本不含对映体。
类似地,术语“分离的(isolated)”指包括至少85-90%重量计,优选95-98%重量计,并且更优选99-100%重量计的该化合物的化合物组合物,余量包含其它的化学种类或对映体。
如本文中所使用的,术语“烷基”,除非另外说明,指的是饱和的直链、支链或环的一级、二级或三级烃,包括取代的和未取代的烷基基团两者。所述烷基基团可任选地由不妨碍反应的或者在工艺中提供改善的任意部分取代,包括但不限于卤素、卤代烷基、羟基、羧基、酰基、芳基、酰氧基、氨基、酰氨基、羧基衍生物、烷基氨基、二烷基氨基、芳基氨基、烷氧基、芳氧基、硝基、氰基、磺酸、巯基、亚胺、磺酰基、硫基(sulfanyl)、亚磺酰基、磺胺基(sulfamonyl)、酯、羧酸、酰胺、膦酰基、氧膦基、磷酰基、膦、硫酯、硫醚、酰卤、酸酐、肟、肼、氨基甲酸酯、膦酸、膦酸酯,未保护的或必要时被保护的,如本领域技术人员已知的,例如,如Greene,等,ProtectiveGroupsinOrganicSynthesis,JohnWileyandSons,SecondEdition,1991中所教导的,其通过引用并入本文。特别包括CF3和CH2CF3。
在文中,不论何时使用术语C(烷基范围),所述术语独立地包括那一类的每个成员,犹如具体并分别陈述。术语“烷基”包括C1-22烷基部分,并且术语“低级烷基”包括C1-6烷基部分。本领域普通技术人员理解,相关烷基原子团通过使用后缀“-基”替换后缀“-烷”命名。
术语“烯基”指不饱和的烃原子团,直链的或支链的,只要(insomuchas)它包含一个或多个双键。本文中公开的烯基基团可任选地由不会对反应工艺有不利影响的任意部分取代,包括但不限于对烷基部分上的取代基描述的那些。烯基基团的非限制性的例子包括乙烯、甲基乙烯、异亚丙基、1,2-乙烷-二基、1,1乙烷-二基、1,3-丙烷-二基、1,2-丙烷-二基、1,3-丁烷-二基和1,4-丁烷-二基。
术语“炔基”指不饱和的无环的烃原子团,直链的或支链的,只要它包含一个或多个三键。所述炔基基团可任选地由不会对反应工艺有不利影响的任意基团取代,包括但不限于上文对烷基部分描述的那些。合适的炔基基团的非限制性的例子包括乙炔基、丙炔基、羟基丙炔基、丁炔-1-基、丁炔-2-基、戊炔-1-基、戊炔-2-基、4-甲氧基戊炔-2-基、3-甲基丁炔-1-基、己炔-1-基、己炔-2-基和己炔-3-基、3,3-二甲基丁炔-1-基原子团。
术语“烷基氨基”或“芳基氨基”分别指具有一个或两个烷基或芳基取代基的氨基基团。
术语“被保护”,如在本文中使用并且除非另外定义,指被加入氧、硫、氮或磷原子以防止它进一步反应或用于其它目的的基团。多种氧和氮保护性基团是有机合成领域技术人员已知的,并且被描述在例如Greene等,ProtectiveGroupsinOrganicSynthesis,supra中。
术语“芳基”,单独的或组合的,意为包含一个、两个或三个环的碳环芳香体系,其中所述环可以悬挂(pendent)的方式连接在一起或者可以是稠合的(fused)。芳基的非限制性的例子包括苯基、联苯基或萘基,或者从芳环去除氢后残留的其它芳香族基团。术语芳基包括取代的和未取代的部分两种。所述芳基基团可任选地由不会对在本文中描述的用于制备所述化合物的工艺有不利影响的任意部分取代,包括但不限于上文对烷基部分描述的那些。取代的芳基的非限制性的例子包括杂芳基氨基、N-芳基-N-烷基氨基、N-杂芳基氨基-N-烷基氨基、杂芳烷氧基、芳基氨基、芳烷基氨基、芳硫基、单芳基酰氨基磺酰基、芳基磺酰氨基、二芳基酰氨基磺酰基、单芳基酰氨基磺酰基、芳基亚磺酰基、芳基磺酰基、杂芳基芳硫基、杂芳基亚磺酰基、杂芳基磺酰基、芳酰基、杂芳酰基、芳烷酰基、杂芳烷酰基、羟基芳烷基、羟基杂芳烷基、卤代烷氧基烷基、芳基、芳烷基、芳氧基、芳烷氧基、芳氧基烷基、饱和杂环基、部分饱和的杂环基、杂芳基、杂芳氧基、杂芳氧基烷基、芳基烷基、杂芳基烷基、芳基烯基和杂芳基烯基、芳烷氧基羰基(carboaralkoxy)。
术语“烷芳基”或“烷基芳基”指具有芳基取代基的烷基基团。术语“芳烷基”或“芳基烷基”指具有烷基取代基的芳基基团。
如在本文中使用的术语“卤代”包括氯代、溴代、碘代和氟代。
术语“酰基”指羧酸酯,在其中,所述酯基团的非羰基部分选自直链、支链或环烷基或低级烷基、烷氧基烷基(包括但不限于甲氧基甲基)、芳烷基(包括但不限于苄基)、芳氧基烷基(例如苯氧基甲基)、芳基(包括但不限于由卤素(F、Cl、Br、I)、烷基(包括但不限于C1、C2、C3和C4)或烷氧基(包括但不限于C1、C2、C3和C4)任选地取代的苯基)、磺酸酯(例如烷基或芳烷基磺酰基,包括但不限于甲磺酰基)、单、二或三磷酸酯、三苯甲基或单甲氧基三苯甲基、取代的苄基、三烷基甲硅烷基(例如,二甲基叔丁基甲硅烷基)或二苯基甲基甲硅烷基。在所述酯中的芳基基团最优包括苯基基团。术语“低级酰基”指在其中非羰基部分为低级烷基的酰基基团。
术语“烷氧基”和“烷氧基烷基”包括具有烷基部分的直链或支链含氧原子团,例如甲氧基原子团。术语“烷氧基烷基”也包括烷基原子团,所述烷基原子团具有一个或多个与所述烷基原子团连接的烷氧基原子团,即,形成单烷氧基烷基和二烷氧基烷基原子团。所述“烷氧基”原子团可进一步由一个或多个卤素原子(例如氟、氯或溴)取代,以提供“卤代烷氧基”原子团。所述原子团的例子包括氟甲氧基、氯甲氧基、三氟甲氧基、二氟甲氧基、三氟乙氧基、氟乙氧基、四氟乙氧基、五氟乙氧基和氟丙氧基。
术语“烷基氨基”表示分别包含一个或两个与氨基原子团连接的烷基原子团的“单烷基氨基”和“二烷基氨基”。术语芳基氨基表示分别包含一个或两个与氨基原子团连接的芳基原子团的“单芳基氨基”和“二芳基氨基”。术语“芳烷基氨基”包括与氨基原子团连接的芳烷基原子团。术语芳烷基氨基表示分别包含一个或两个与氨基原子团连接的芳烷基原子团的“单芳烷基氨基”和“二芳烷基氨基”。术语芳烷基氨基还表示包含一个芳烷基原子团和与氨基原子团连接的一个烷基原子团的“单芳烷基单烷基氨基”。
如本文中所使用的,术语“杂原子”指氧、硫、氮和磷。
如本文中所使用的,术语“杂芳基”或“杂芳烃基”指在芳香烃环中包括至少一个硫、氧、氮或磷或者在芳香体系中包括两个或多个杂原子(O、S、N、P)的组合。五元和六元环杂芳基都被考虑在本文中,此时五元和六元环连接至苯环,例如苯并呋喃、苯并噻吩、苯并吡咯等。
术语“杂环”、“杂环基”和环杂烷基指非芳香族环基基团,其中在所述环中具有至少一个杂原子,例如氧、硫、氮或磷。
杂芳基和杂环基基团的非限制性的例子包括呋喃基(furyl)、呋喃基(furanyl)、吡啶基、嘧啶基、噻吩基、异噻唑基、咪唑基、四唑基、吡嗪基、苯并呋喃基、苯并噻吩基、喹啉基、异喹啉基、苯并噻吩基、异苯并呋喃基、吡唑基、吲哚基、异吲哚基、苯并咪唑基、嘌呤基、咔唑基、恶唑基、噻唑基、异噻唑基、异噻唑基、1,2,4-噻二唑基、异恶唑基、吡咯基、喹唑啉基、噌啉基、酞嗪基、黄嘌呤、次黄嘌呤(hypoxanthinyl)、噻吩、呋喃、吡咯、异吡咯、吡唑、咪唑、1,2,3-***、1,2,4-***、恶唑、异恶唑、噻唑、异噻唑、嘧啶或哒嗪和蝶啶、氮丙啶、噻唑、异噻唑、1,2,3-恶二唑、噻嗪、吡啶、吡嗪、哌嗪、吡咯烷、oxaziranes、吩嗪、吩噻嗪、吗啉基、吡唑基、哒嗪基、吡嗪基、喹喔啉基、黄嘌呤、次黄嘌呤、喋啶、5-氮杂胞苷基、5-氮杂尿嘧啶基、***并吡啶基、咪唑并吡啶基、吡咯并嘧啶基、吡唑并嘧啶基、腺嘌呤、N6-烷基嘌呤、N6-苄基嘌呤、N6-卤代嘌呤、N6-乙烯基嘌呤、N6-炔基嘌呤、N6-酰基嘌呤、N6-羟基烷基嘌呤、N6-烷硫基嘌呤、胸腺嘧啶、胞嘧啶、6-氮杂嘧啶、2-巯基嘧啶、尿嘧啶、N5-烷基嘧啶、N5-苄基嘧啶、N5-卤代嘧啶、N5-乙烯基哌嗪、N5-炔基嘧啶、N5-酰基嘧啶、N5-羟基烷基嘌呤和N6-烷硫基嘌呤以及异恶唑基。如上文对芳基的描述,所述咋芳基基团可任选地被取代。所述杂环基或杂芳基基团可任选地被一种或多种取代基取代,所述取代基选自卤素、卤代烷基、烷基、烷氧基、羟基、羧基衍生物、酰氨基、氨基、烷基氨基、二烷基氨基。如果需要,所述杂芳基可部分或完全氢化。作为非限制性的例子,可使用二氢吡啶代替吡啶。在需要或希望时,在杂环基或杂芳基基团上功能性氧和氮可以是被保护的。合适的保护性基团是本领域技术人员熟知的,并且包括三甲基甲硅烷基、二甲基己基甲硅烷基、叔丁基二甲基甲硅烷基和叔丁基二苯基甲硅烷基、三苯甲基或取代的三苯甲基、烷基基团、酰基基团例如乙酰基和丙酰基、甲磺酰基和对甲苯磺酰基。所述杂环基或杂芳基基团可由不会对反应有不利影响的任意部分取代,包括但不限于上文对芳基描述的那些。
如在本文中所使用的,术语“宿主”指病毒可在其中复制的单细胞或多细胞有机体,包括但不限于细胞株和动物,并且优选人类。可选地,所述宿主可携带一部分病毒基因组,其复制或作用可由本发明的化合物改变。术语宿主特别指被感染的细胞,被转染所有或部分病毒基因组的细胞和动物,特别是灵长类(包括但不限于黑猩猩)和人类。在本发明的大多数动物应用中,所述宿主为人类患者。然而,在某些适应症中,本发明也已清楚地考虑了兽医学应用(例如在治疗黑猩猩中的用途)。
术语“肽”指包含两个至一百个氨基酸的多种天然或合成化合物,所述氨基酸通过一个氨基酸的羧基基团至另一个的氨基基团连接。
术语“药学上可接受的盐或前药”在整个说明书中使用,以描述一种化合物的任意药学上可接受的形式,其在向患者施用时,提供了母体化合物。药学上可接受的盐包括衍生自药学上可接受的无机或有机碱和酸的那些。合适的盐包括在药学领域熟知的众多其它酸中衍生自碱金属(例如钾和钠)、碱土金属(例如钙和镁)的那些。药学可接受的前药指在宿主中被新陈代谢(例如被水解或氧化)以形成本发明的化合物的化合物。前药的典型的例子包括在活性化合物的功能性部分上具有生物学上易分解的保护性基团的化合物。前药包括可被氧化、还原、胺化、脱氨基、羟基化、脱羟基、水解、脱水、烷基化、脱烷基、酰化、脱酰基、磷酸化或去磷酸化以生产活性化合物的化合物。本发明的化合物的前药形式可具有抗病毒活性,可被新陈代谢以形成显示所述活性的化合物,或者两者都可以。
II活性化合物
本文中描述的化合物具有以下通式:
或其药学上可接受的盐或前药,其中
J和J1可存在或不存在,并且当存在时,独立地选自低级烷基(C1-C6)、芳基、芳烷基、烷氧基、芳氧基、杂环基、杂环氧基、酮基、羟基、氨基、芳基氨基、羧基烷基、甲酰氨基(carboxamido)烷基、卤素、氰基、甲酰基、磺酰基或磺酰氨基;并且
R为C1-C10烷基,C3-8环烷基、芳基、杂芳基或杂环基。
III.立体异构和多态性
本文中所述化合物可具有不对称中心并且以外消旋体、外消旋混合物、单个(individual)非对映异构体或对映体的形式出现,本发明中包括所有的同质异构形式。具有手性中心的本发明的化合物可以光学活性或外消旋的形式存在或被分离。许多化合物可显示多态性。本发明包含本发明化合物的外消旋、光学活性、多态或立体异构体形式,或它们的混合物,它们具有本文中描述的有用的性能。所述光学活性形式的制备可通过,例如通过重结晶技术拆分外消旋形式,通过由光学活性原料合成,通过手性合成或通过使用手性固定相层析分离或通过酶法拆分。
所述化合物的光学活性形式可使用本领域已知的任意方法制备,包括但不限于,通过重结晶技术拆分外消旋形式,通过由光学活性原料合成,通过手性合成,或通过使用手性固定相层析分离。
得到光学活性材料的方法的例子包括至少以下所述。
i)晶体的物理分离:一种技术,借此,单一对映体的宏观晶体被手动分离。如果存在分离的对映体的晶体,即,所述材料是成团的,并且所述晶体在视觉上是清楚可见的,那么可使用本技术;
ii)同时结晶:一种技术,借此,单一对映体从外消旋体的溶液中分离结晶,其只有当后者在固体状态是成团的时候才是可能的;
iii)酶拆分:一种技术,借此,借助于对映体与酶反应的不同速率,部分或完全分离外消旋体;
iv)酶不对称合成:一种合成技术,借此,所述合成的至少一步使用酶反应以得到对映异构纯或富集的所需对映体的合成前体;
v)化学不对称合成:一种合成技术,借此,所需对映体在产生产品中的不对称(即,手性)的条件下由非手性前体合成,其可使用手性催化剂或手性助剂实现;
vi)非对映体分离:一种技术,借此,外消旋化合物与对映异构纯的试剂(所述手性助剂)反应,将单一对映体转化为非对映体。然后借助于它们现在更加明显的结构区别通过色谱法或结晶分离所得到的非对映体并且随后去除所述手性助剂以得到所需对映体;
vii)第一和第二级不对称转化:一种技术,借此,使来自于外消旋体的非对映体平衡,以在来自于所需对映体的非对映体溶液中占多数,或者其中来自于所需对映体的非对映体的优先结晶扰乱所述平衡,使得最终基本上所有材料转化为来自于所需对映体的结晶的非对映体。随后,所需对映体从所述非对映体释放;
viii)动力学拆分:该技术是指借助于对映体与手性、非外消旋试剂或者催化剂在动力学条件下不同的反应速率,实现将外消旋体部分或者完全拆分(或者将部分拆分的化合物进一步拆分);
ix)由非外消旋前体对映异构合成:一种合成技术,借此,从非手性原料得到所需对映异构体并且在合成过程中立体化学的完整性没有或者只是略微受到影响;
x)手性液相色谱法:一种技术,借此,在液体流动相中借助于外消旋体的对映异构体与固定相相互作用不同而将其分离(包括但不限于通过手性HPLC)。固定相可由手性材料制成,或者流动相可包含另外的手性试剂,以获得所述不同的相互作用;
xi)手性气相色谱法:一种技术,借此,外消旋体挥发并且借助于它们在气态流动相中与含有固定的非外消旋手性吸附相的柱相互作用的不同而将对映异构体分离;
xii)使用手性溶剂萃取:借助于一种对映异构体优先溶解于特定的手性溶剂中而分离对映异构体;
xiii)透过手性膜传输:一种技术,借此,放置外消旋体与薄膜屏障直接接触。在该方法中将外消旋体与薄膜屏障直接接触。该屏障典型地分离两种可混溶的流体,一种包含所述外消旋体,并且驱动力(例如浓度或压力差异)引起透过所述膜屏障的优先传输。只允许外消旋体中的一种对映体通过的膜的非外消旋手性特性,造成了分离的发生。
将手性色谱法(包括但不限于模拟移动床色谱法)用于一个实施方案中。所中手性固定相可通过市售得到。
IV.化合物盐或前药制剂
在化合物具有足够的碱性或酸性以形成稳定的无毒的酸或碱盐的情况下,作为药学上可接受的盐的化合物的施用可能是适当的。药学上可接受的盐的例子为酸形成的有机酸加成盐,所述酸形成药学上可接受的阴离子,例如,甲苯磺酸酯、甲磺酸盐、乙酸盐、柠檬酸盐、丙二酸盐、酒石酸盐、琥珀酸盐、苯甲酸盐、抗坏血酸盐、α-酮戊二酸和α-磷酸甘油。也可形成合适的无机盐,包括但不限于,硫酸盐、硝酸盐、碳酸盐和碳酸氢盐。
药学上可接受的盐可使用本领域熟知的标准程序得到,例如,通过使足够碱性的化合物例如胺与合适的酸反应,提供一种药学上可接受的阴离子。也可制造羧酸的碱金属(例如,钠、钾或锂)或碱土金属(例如,钙、镁)盐。
V.治疗方法
感染HCV或其基因片段的宿主(包括但不限于人类)可通过在药学上可接受的载体或稀释剂存在下将有效量的活性化合物或其药学上可接受的前药或盐施用至患者来治疗。可通过任意合适的路径施用所述活性材料,例如,以液体或固体形式,口服施用、非肠道施用、静脉施用、皮内施用、皮下施用或局部施用。
VI.组合或可选疗法
在一个实施方案中,本发明的化合物可与至少一种其它的抗病毒剂一起应用。
被批准的或在临床前和临床研究中的抗HCV化合物的表
VII.药物组合物
感染丙型肝炎病毒(“HCV”)或其基因片段的宿主(包括但不限于人类)可通过在药学上可接受的载体或稀释剂存在下将有效量的活性化合物或其药学上可接受的前药或盐施用至患者来治疗。可通过任意合适的路径施用所述活性材料,例如,以液体或固体形式,口服施用、非肠道施用、静脉施用、皮内施用、皮下施用或局部施用。
所述化合物的优选剂量在每天约0.1和约100mg/kg受体体重之间,更一般地约1和50mg/kg受体体重之间,并且优选地约1和约20mg/kg受体体重之间的范围内。所述药学上可接受的盐和前药的有效剂量范围可基于待给药的母体化合物的重量来计算。如果所述盐或前药本身显示出有效性,那么,所述有效剂量可如上文使用所述盐或前药的重量估算,或者通过本领域技术人员已知的其它方法估算。
所述化合物以单位任意合适的剂型方便地施用,包括但不限于,包含7至3,000mg,优选70至1400mg活性成分每单位剂型的一种。50至1,000mg的口服剂量通常是方便的。
理想地,应当施用所述活性成分以实现约0.2至70μM,优选约1.0至15μM的所述活性化合物的峰值血浆浓度。这可通过以下方式实现,例如通过静脉注射所述活性成分的0.1至5%溶液(任选地,在盐水中),或者作为所述活性成分的丸剂施用。
在所述药物组合物中活性化合物的浓度将取决于所述药物的吸收、失活和***速率以及本领域技术人员已知的其它因素。应当注意的是剂量值也随着待缓和的病况的严重性变化。还应理解的是对于任意特殊的受试者,应当随着时间根据个体需要以及施用或监督所述组合物的施用的人员的专业判断来调整具体的剂量方案,并且本文中阐明的浓度范围仅仅是示例性的并且不是意在限制所要求的组合物的范围或实践。所述活性成分被一次施用,或可分成数个更小的剂量以不同的时间间隔施用。
所述活性化合物的优选的施用方式为口服。口服组合物将通常包括惰性稀释剂或可食用载体。它们可封闭在明胶胶囊内或压缩在片剂内。为了口服治疗施用的目的,所述活性化合物可掺入赋形剂并且以片剂、锭剂或胶囊的形式使用。药学上可相容的粘结剂和/或佐剂(adjuvant)材料可作为所述组合物的一部分被包括。
所述片剂、丸剂、胶囊剂、锭剂等等可包含任意以下成分或具有相似性质的化合物:粘结剂,例如微晶纤维素、黄蓍树胶或明胶;辅料,例如淀粉或乳糖,崩解剂,例如藻酸,Primogel或玉米淀粉润滑剂,例如硬脂酸镁或Sterotes;助流剂,例如胶态二氧化硅;甜味剂,例如蔗糖或糖精(sweetener);或调味剂,例如suchas薄荷、水杨酸甲酯或橙味剂。当剂量单位形式为胶囊时,除了上述类型的材料外,它可包含液体载体,例如脂肪油。此外,单位剂型可包含改变所述剂量单位的物理形态的多种其它的材料,例如,包含糖、虫胶或其它肠溶制剂的涂层。
所述化合物可作为酏剂,混悬液、糖浆、圆片(wafer)、口香糖等等的一种组分施用。除了所述活性化合物(一种或多种)外,糖浆可包含作为甜味剂的蔗糖或糖精(sweetener)以及某些防腐剂、染料和着色剂以及香料。
所述化合物或其药学上可接受的前药或盐还可与不损害所需作用的其它活性材料混合,或与增补所需作用的材料混合,例如抗生素、抗真菌剂、抗炎药或其它抗病毒剂,包括但不限于,核苷化合物。用于肠胃外、真皮内、皮下或局部应用的溶液或混悬液可包括以下组分无菌稀释剂例如注射用水、盐溶液、固定油、聚乙二醇、甘油、丙二醇或其它合成的溶剂;抗菌剂,例如,苄醇或羟苯甲酸甲酯;抗氧化剂,例如,抗坏血酸或亚硫酸氢钠;螯合剂,例如,乙二胺四乙酸;缓冲剂,例如,乙酸盐、柠檬酸盐或磷酸盐,以及用于调节张力的试剂,例如,氯化钠或葡萄糖。所述母本制剂(parentalpreparation)可被封闭在玻璃或塑料制成的安瓶、一次性注射器或多剂量小瓶中。
如果静脉注射施用,优选的载体为生理盐水或磷酸盐缓冲盐水(PBS)。
在一个优选的实施方案中,使用载体制备活性化合物,所述载体将保护所述化合物免于从身体快速消除,例如控释制剂,包括但不限于,埋植和微胶囊化给药***。可使用可生物降解的、生物相容性聚合物,例如乙烯乙酸乙烯酯、聚酐、聚乙醇酸、胶原、聚原酸酯和聚乳酸。例如,肠溶涂层的化合物可用于保护胃酸造成的裂解。用于制备所述制剂的方法对于本领域的技术人员将是明显的。合适的材料可通过市售得到。
脂质体混悬液(包括但不限于靶向对病毒抗原具有单克隆抗体的被感染细胞的脂质体)也可优选作为药学上可接受的载体。这些可根据本领域技术人员已知的方法制备,例如,如美国专利第4,522,811号(通过引用并入)中所描述的。例如,脂质体制剂可通过以下步骤制备:将一种或多种合适的脂质(例如硬脂酰磷脂酰乙醇胺,硬脂酰磷脂酰胆碱,花生酰(arachadoyl)磷脂酰胆碱,和胆固醇)溶解在无机溶剂中,随后将所述无机溶剂蒸发,在容器的表面上遗留下干燥的脂质薄膜。然后将所述活性化合物的水性溶液引入至所述容器中。然后用手搅动所述容器,以从所述容器的各面释放脂质材料并且分散脂质聚集体,因此形成脂质体混悬液。
用于描述本发明的术语是通常使用的并且是本领域技术人员已知的。如在本文中所使用的,以下缩写词具有所表明的含义:
IX.制备活性化合物的一般程序
用于制备本发明的化合物的方法可如以下“具体实施例”部分中详细描述的来准备,或通过本领域技术人员已知的其它方法准备。一个本领域的普通技术人员将理解,这些方案绝不是限制性的并且可进行许多细节的变化,而不脱离本发明的精神和范围。
具体实施例
代表本发明的具体化合物按照以下实施例和反应顺序制备;描绘反应顺序的实施例和图表通过举例说明的方式提供,以帮助理解本发明,并且不应当被解释为以任意方式限制随后所附的权利要求书中陈述的发明。本化合物也卡在随后的实施例中被用作中间体,以生成本发明的其它化合物。已没有必要做出尝试以优化在任意反应中得到的收率。本领域技术人员将知道如何通过常规变化反应时间、温度、溶剂和/或试剂来提高所述收率。
试剂和溶剂可从商业供应商得到并且使用而无需进一步纯化。二氯甲烷通过CaCl2干燥并蒸馏并且在氩气下通过分子筛存储。四氢呋喃在氩气下通过纳/二苯甲酮干燥并且在使用前蒸馏。闪式层析纯化(Flashchromatographypurifications)在作为固定相的MachereyNalgel硅胶柱(40-63μM)上进行或者使用填充的RediSep柱在TeledyneIscoCombiflashCompanion仪上进行。分析的高效液相色谱-质谱分析(HPLC-MS):HPLC-MS条件A1:HPLS-MS在装备有光电二极管阵列检测器Waters996和WatersMicromassQ-Tof的WatersAlliance2790仪上使用BDSHypersil50x2.1,3μm进行。洗脱条件包含线性梯度:在20分钟内0%-80%的MeCN/H2O(在正离子模式中包含0.1%TFA并且在负离子模式中不含TFA),流速0.2mL/min。HPLC-MS条件A2:HPLS-MS在装备有光电二极管阵列检测器Waters996和WatersMicromassQ-Tof的WatersAlliance2790仪上使用NucleodurC18Pyramid50x2.1,3μm进行。洗脱条件包含线性梯度:在20分钟内0%-80%的MeCN/H2O(在正离子模式中包含0.1%TFA并且在负离子模式中不含TFA),流速0.3mL/min。
HPLC-MS条件B:HPLS-MS在装备有光电二极管阵列检测器AgilentG1315A、polymerlabsELS2100(DEDL)检测器和用于质谱分析的AgilentSimpleQuadESI的AgilentHP-1100仪上使用AgilentZorbaxXDB-C18RPC1845x4.6,3.5μm进行。洗脱条件包含线性梯度:在4.5分钟内10%-100%的MeCN/H2O(包含0.05%TFA),流速1.5mL/min。
低分辨率质谱(MS)由应用生物***公司SCIEX3200QTRAP在大气压电离条件(API)下在正(ES+)或负(ES-)模式得到。
高分辨率质谱(HRMS)由珀金埃尔默仪器得到。
在氘化的溶剂中在250MHz1H和63MHz13CNMR在BrukerAvance250上记录NMR谱图并且其相对于溶剂残留峰以ppm计(referencedinppm)(见参考文献GottliebH.E.等.J.OrgChem1997(2)7512-7515)。
实施例1
P2羟基脯氨酸衍生物的合成:
方案1:P2羟基脯氨酸衍生物的化学路径
实施例2
10的合成:
方案2:10的合成路径
可制备化合物10的类似物(在其中J和J1存在),例如,通过使用原料的取代形式:
其中J和J1如在本文中所定义的,或者,当这些部分将妨碍在方案I中描述的偶联化学过程时,是被保护的基团,所述被保护的基团可在所述偶联化学过程完成之后或在整体合成中的末期步骤转化成为所需J和J1部分。
该式的化合物是已知的,并且可仅仅使用常规实验制备。本领域技术人员将容易理解,取代基至所述芳环上的结合可很容易地实现,或者在制备核心结构之前,或者在之后,即,在关键的偶联步骤过程中可存在所述取代基,或者可在已制备未被取代的化合物(即,不具有所述J和/或J1部分)之后添加所述取代基。所述取代基可提供在它们自身内和它们自身的有用的性能,或者用作进一步合成精制用的柄(handle)。一个附加条件是,所述取代基或者应当在所述合成条件下可以存在,或者否则应当在所述合成完成之后添加。
例如,所述芳环可以是使用各种已知的程序卤化的,所述程序根据具体的卤素而变化。合适的试剂的例子包括溶于浓缩的HBr的溴/水、氯化亚砜、pyr-ICL、氟和大孔树脂-A。在芳环的被重氮化的位置中具有取代基的众多其它类似物可由相应的苯胺化合物通过重氮盐中间体合成。所述重氮盐中间体可使用已知的化学过程制备,例如,在矿物酸存在下用亚硝酸钠处理芳香胺例如苯胺。
重氮盐可由苯胺形成,反过来所述苯胺可由硝基苯制备(并且类似的胺取代的杂芳环可由硝基取代的杂芳环制备)。可通过与亚硝酸盐反应将硝基衍生物还原为胺类化合物,典型地在酸存在下。其它被取代的类似物可使用本领域技术人员已知的一般技术由重氮盐中间体(包括,但不限于,羟基、烷氧基、氟、氯、碘、氰基和巯基)生产。同样地,烷氧基类似物可通过使重氮盐与醇类反应制成。所述重氮盐也可用于合成氰基或卤代化合物,如本领域技术人员将要知道的。巯基取代基可使用在Hoffman等,J.Med.Chem.36:953(1993)中描述的技术得到。这样生成的硫醇可转而通过与氢化钠和合适的烷基溴反应被转化成为烷硫基(alkylthio)取代基。然后随后的氧化将提供砜。上述化合物的酰胺类似物可通过使用有机合成领域的技术人员已知的技术使相应的氨基化合物与合适的酸酐或酰基氯反应制备。
羟基取代的类似物可用于通过与合适的酸、酰基氯或酸酐反应制备相应的烷酰氧基取代的化合物。同样地,所述羟基化合物是芳氧基和杂芳氧基两者通过在缺电子芳香环上的亲核芳香取代的前体。该化学过程是有机合成领域技术人员熟知的。醚类衍生物也可通过使用卤代烃和合适的碱烷化或通过通常使用三烷基或三芳基膦和偶氮二羧酸二乙酯的Mitsunobu化学过程由羟基化合物制备。参见Hughes,Org.React.(N.Y.)42:335(1992)和Hughes,Org.Prep.Proced.Int.28:127(1996)fortypicalMitsunobuconditions。
可使氰基取代的类似物水解,以提供相应的甲酰胺基取代的化合物。进一步的水解导致形成了相应的羧酸取代的类似物。用氢化铝锂还原氰基取代的类似物产生了相应的氨甲基类似物。酰基取代的类似物可通过使用有机合成领域技术人员已知的技术与合适的烷基锂反应由相应的羧酸取代的类似物制备。
羧酸取代的类似物可通过与合适的醇和酸催化剂反应转化成为相应的酯。可使用硼氢化钠或氢化铝锂还原具有酯基的化合物,以生产相应的羟甲基取代的类似物。这些类似物反过来可通过使用常规技术与氢化钠和合适的卤代烷反应转化成为具有酯部分的化合物。可选地,所述羟甲基取代的类似物可与对甲苯磺酰氯反应,以提供相应的对甲苯磺酰氧甲基类似物,其可通过用亚硫酰氯和合适的烷基胺顺序处理转化成为相应的烷基氨酰基类似物。已知这些酰胺中的某些可很容易地经受亲核酰基取代以生产酮类。
羟基取代的类似物可用于通过与N-烷基-或N-芳基异氰酸酯反应制备N-烷基-或N-芳氨基甲酰氧基取代的化合物。氨基取代的类似物可通过使用有机合成领域技术人员已知的技术分别与氯甲酸烷基酯和N-烷基或-N-芳基异氰酸酯反应用于制备烷氧基甲酰胺基取代的化合物和尿素衍生物。
类似地,苯环可使用已知的化学过程取代,包括上文讨论的反应。例如,在硝基苯上的硝基基团可与亚硝酸钠反应以形成重氮盐,并且如上文所讨论操作所述重氮盐以在苯环上形成各种取代基。
上述取代基可因此被添加至起始苯环上,并且被掺入本文中描述的最终化合物中。
实施例3
HepG2细胞中线粒体毒性测定:
i)化合物对细胞互长和乳酸生产的影响:对HepG2细胞生长的影响通过在0μM、0.1μM、1μM、10μM和100μM药物存在下培养孵育细胞测定。将细胞(每孔5x104)置于最小必需培养基中的12孔细胞培养簇中并且在37℃培养4天,所述最小必需培养基具有补充了10%胎牛血清、1%丙酮酸钠、1%青霉素/链霉素的非必需氨基酸。在所述孵育期的最后,使用血细胞计测定细胞数目。也由Pan-ZhouX-R,CuiL,ZhouX-J,SommadossiJ-P,Darley-UsmerVM.″DifferentialeffectsofantiretroviralnucleosideanalogsonmitochondrialfunctioninHepG2cells″Antimicrob.AgentsChemother.2000;44:496-503教导。为了测量化合物对乳酸生产的影响,将来自于原种培养(stockculture)的HepG2细胞稀释并以每孔2.5x104个细胞置于12孔培养板中。添加多种浓度(0μM、0.1μM、1μM、10μM和100μM)的测试化合物,将所述培养物在37℃在潮湿的5%CO2大气中孵育4天。在第4天测定每个孔中的细胞数目并且收集培养基。将所述培养基过滤并使用比色乳酸分析法(Sigma-Aldrich)测定所述培养基中的乳酸含量。由于乳酸产品可被看做是线粒体功能受损的标记,因此在测试化合物存在下在细胞生长中检测到的提高的乳酸生产水平将表明药物诱导的细胞毒性效应。
ii)化合物对线粒体DNA合成的影响:已进行实时PCR测定以精确定量线粒体DNA含量(参见StuyverLJ,LostiaS,AdamsM,MathewJS,PaiBS,GrierJ,TharnishPM,ChoiY,ChongY,ChooH,ChuCK,OttoMJ,SchinaziRF.Antiviralactivitiesandcellulartoxicitiesofmodified2′,3′-dideoxy-2′,3′-didehydrocytidineanalogs.Antimicrob.AgentsChemother.2002;46:3854-60)。该测定被用于在本申请中描述的所有研究中,其测定了测试化合物对线粒体DNA含量的影响。在这一测定中,以5,000细胞/孔将第低传代数(low-passage-number)HepG2细胞接种于胶原蛋白包被的96孔板中。将化合物添加至所述培养基以得到0μM、0.1μM、10μM和100μM的最终浓度。在第7个培养日,通过使用可通过市售得到的柱(RNeasy96试剂盒;Qiagen)制备细胞核酸。这些试剂盒共纯化RNA和DNA,并且因此,将全部的核酸从所述柱中洗脱。使用多重Q-PCR程序以及对于靶及参照物扩增(referenceamplifications)都合适的引物和探针,从5μl洗脱的核酸扩增线粒体细胞色素c氧化酶亚基II(COXII)基因和β-肌动蛋白或rRNA基因。对于COXII,分别使用以下的有义、探针和反义引物:5′-TGCCCGCCATCATCCTA-3′,5′-四氯-6-羧基荧光素-TCCTCATCGCCCTCCCATCCC-TAMRA-3′和5′-CGTCTGTTATGTAAAGGATGCGT-3′。对于β-肌动蛋白基因(基因库登录号E01094)的外显子3,所述有义、探针和反义引物分别为5′-GCGCGGCTACAGCTTCA-3′,5′-6-FAMCACCACGGCCGAGCGGGATAMRA-3′和5′-TCTCCTTAATGTCACGCACGAT-3′。用于rRNA基因的引物和探针可从应用生物***公司市售得到。由于得到了对于所有基因相等的扩增效率,使用竞争性CT法研究线粒体DNA合成的可能的抑制。所述竞争性CT法使用计算公式,在其中,将靶(COXII基因)的量对内源参考(endogenousreference)(β肌动蛋白或rRNA基因)的量标准化是相对于校准器(在第7天没有药物的一个参照)的。用于本方法的计算公式由2-ΔΔCT给出,其中所述ΔΔCT为(平均靶测试样品的CT-目标对照的CT)-(平均参照测试的CT-参照物对照的CT)(参见JohnsonMR,KWang,JBSmith,MJHeslin,RBDiasio.Quantitationofdihydropyrimidinedehydrogenaseexpressionbyreal-timereversetranscriptionpolymerasechainreaction.Anal.Biochem.2000;278:175-184)。在药物存在下生长的细胞中线粒体DNA含量的减少将表明线粒体毒性。
iii)电子显微形态学评价:NRTI诱导的毒性已经显示会造成线粒体中的形态学变化(例如,嵴丧失、基质溶解和溶胀以及脂滴形成),其可使用透射电子显微镜观察分析超微结构(参见CuiL,SchinaziRF,GosselinG,ImbachJL.ChuCK,RandoRF,RevankarGR,SommadossiJP.EffectofenantiomericandracemicnucleosideanalogsonmitochondrialfunctionsinHepG2cells.Biochem.Pharmacol.1996,52,1577-1584;LewisW,LevineES,GriniuvieneB,TankersleyKO,ColacinoJM,SommadossiJP,WatanabeKA,PerrinoFW.FialuridineanditsmetabolitesinhibitDNApolymerasegammaatsitesofmultipleadjacentanalogincorporation,decreasemtDNAabundance,andcausemitochondrialstructuraldefectsinculturedhepatoblasts.ProcNatlAcadSciUSA.1996;93:3592-7;Pan-ZhouXR,LCui,XJZhou,JPSommadossi,VMDarley-Usmar.DifferentialeffectsofantiretroviralnucleosideanalogsonmitochondrialfunctioninHepG2cells.Antimicrob.AgentsChemother.2000,44,496-503)。例如,与10μM非阿尿苷(FIAU;1,2′-脱氧-2′-氟-1-D-***呋喃糖基-5-碘-尿嘧啶)一起孵育的HepG2细胞的电子显微图显示了增大的线粒体的存在,所述线粒体具有与线粒体功能障碍相一致的形态学变化。为了确定化合物是否促进线粒体中的形态学变化,将HepG2细胞(2.5×104个细胞/mL)在0μM、0.1μM、1μM、10μM和100μM测试化合物存在时接种至组织培养皿(35×10mm)中。在第8天,固定细胞,脱水,并包埋入之前描述的Eponas中。制备薄切片,用乙酸双氧铀和柠檬酸铅着色,并且然后使用透射电子显微镜检查。
实施例4
骨髓细胞毒性分析
从CambrexBioscience(Walkersville,MD)市售得到原代人骨髓单核细胞。使用双层软琼脂,在有50单位/mL人重组粒细胞/巨噬细胞集落刺激因子存在下,进行CFU-GM测定,同时BFU-E测定使用含有1单位/mL红细胞生成素的甲基纤维素基质(参见SommadossiJP,CarlisleR.Toxicityof3’-azido-3’-deoxythymidineand9-(1,3-dihydroxy-2-propoxymethyl)guaninefornormalhumanhepatopoieticprogenitorcellsinvitro.Antimicrob.AgentsChemother.1987;31:452-454;Sommadossi,JP,Schinazi,RF,Chu,CK,andXie,MY.ComparisonofCytotoxicityofthe(-)and(+)enantiomerof2’,3’-dideoxy-3’-thiacytidineinnormalhumanbonemarrowprogenitorcells.Biochem.Pharmacol.1992;44:1921-1925)。在来自3个不同供体的细胞中,一式两份地进行每个实验。AZT用作阳性对照。在化合物存在下,在37℃、5%CO2下孵育细胞14-18天,并使用倒置显微镜计数大于50个细胞的集落以测定IC50。通过药物浓度的对数相对于BFU-E存活分数的最小二乘法线性回归分析得到50%抑制浓度(IC50)。使用独立的未配对样品的学生t检验进行统计分析。
实施例5
细胞毒性分析
如以前所述(参见SchinaziR.F.,SommadossiJ.-P.,SaalmannV.,CannonD.L.,XieM.-Y.,HartG.C.,SmithG.A.&HahnE.F.Antimicrob.AgentsChemorger.1990,34,1061-67),可以在Vero、人PBM、CEM(人类淋巴母细胞)、MT-2和HepG2细胞中测定化合物的毒性。包括作为阳性细胞毒性对照的环己酰亚胺,并包括接触溶剂的未处理细胞作为阴性对照。使用前述半数有效方法(参见ChouT.-C.&TalalayP.Adv.EnzymeRegul.1984,22,27-55;Belen’kiiM.S.&SchinaziR.F.AntiviralRes.1994,25,1-11)从浓度-反应曲线得到细胞毒性IC50。
10的数据为
PBM>100μM(17%抑制100μM)
CEM>100μM(11%抑制100μM)
VERO>100(-0.8%抑制100μM)
实施例6
HCV复制子分析1
将含有HCV复制子RNA的Huh7克隆B细胞以5000个细胞/孔接种至96孔板中,并且在接种后立即在10μM一式三份地测试化合物。孵育(37℃,5%CO2)5天后,通过使用来自Gentra的versaGeneRNA纯化试剂盒分离总细胞RNA。在单步多重实时RT-PCR测定中扩增复制子RNA和内部对照(TaqManrRNA对照试剂,AppliedBiosystems)。通过从无药物对照的阈值RT-PCR循环中减去测试化合物的阈值RT-PCR循环(ΔCtHCV)计算化合物的抗病毒有效性。3.3的ΔCt等于在复制子RNA水平的1-log减少(等于少于原料90%)。还通过使用ΔCtrRNA值计算化合物的细胞毒性。(2′-Me-C)用作对照。为了测定EC90和IC50值2,首先将ΔCt:值转化成原料的分数3,并且然后用于计算%抑制。
参考文献:
1.StuyverL等,RibonucleosideanaloguethatblocksreplicationorbovineviraldiarrheaandhepatitisCvirusesinculture.Antimicrob.AgentsChemother.2003,47,244-254.
2.ReedIJ&MuenchH,Asimplemethodorestimatingfiftypercentendpoints.Am.J.Hyg.27:497,1938.
3.AppliedBiosystemsHandbook
结果显示在下表1中:
表1
化合物 | Conc(μM) | DCt HCV | DCt rRNA | HCV | rRNA | EC50 | EC90 | CC50 |
10 | 0.01 | 1.16 | -0.21 | 54.99 | -15.99 | 0.01 | 0.03 | >0.3 |
0.03 | 3.29 | -0.49 | 89.67 | -40.10 | ||||
0.1 | 6.05 | -0.09 | 98.47 | -6.27 | ||||
0.3 | 8.72 | 0.14 | 99.76 | 9.35 | ||||
实施例7
在食蟹猴体内的生物利用度测定
下述程序可以用于测定化合物是否是生物可利用的。在研究开始之前1周内,可以通过外科手术给食蟹猴植入长期静脉导管和皮下静脉访问口(VAP)以便于血液收集,且可以经历体格检查,所述体格检查包括血液学和血清化学评价和体重记录。每只猴(共6只)接受2-20mg/kg剂量水平的化合物,通过静脉内推注(3只猴,IV)或者通过经口腔管饲法(3只猴,PO)。在给药之前称量每个给药注射器以根据重量确定施用的制剂的量。在指定的间隔(给药前大约18-0小时,给药后0-4、4-8和8-12小时),通过收集盘(pancatch)收集尿样,并处理。通过长期静脉导管和VAP或从末梢血管(如果长期静脉导管操作应当不可能的话),同样收集血样(给药前,给药后0.25、0.5、1、2、3、6、8、12和24小时)。分析血样和尿样的最大浓度(Cmax)、达到最大浓度时的时间(TmaX)、曲线下面积(AUC)、剂量浓度的半衰期(TV)、清除率(CL)、稳态体积和分布(Vss)和生物利用度(F)。
实施例8
HCV蛋白酶抑制剂对选定的人类蛋白酶的影响
HCV蛋白酶抑制剂已证明除了与宿主蛋白酶的抑制相关的令人关注的毒性外很好的抗病毒效能。为了避免类似的毒性,评估了新的蛋白酶抑制剂对一批重要的人类蛋白酶的抑制。所测试的酶为弹性蛋白酶(中性粒细胞)、血纤维蛋白溶酶、凝血酶和组织蛋白酶S。
中性白细胞弹性蛋白酶(或白细胞弹性蛋白酶),又称为ELA2(弹性蛋白酶2),是与胰凝乳蛋白酶相同种类的丝氨酸蛋白酶并且具有广泛的底物专一性。由中性粒细胞在炎症过程中分泌,它的主要作用之一是破坏宿主组织内的细菌。(Belaaouaj等,Science289(5482):1185-8)。
纤溶酶是一种丝氨酸蛋白酶,其在血浆中通过纤溶酶原活化剂衍生自纤溶酶原的转化而来(Collen,D.Circulation,93,857(1996))。该酶(EC3.4.21.7)降解许多血浆蛋白,最显著地为纤维蛋白凝块。纤溶酶还与许多病理学和生理学过程例如炎症、肿瘤、新陈代谢、伤口愈合、血管生成、胚胎发育和***相关(Vassalli,J.D等,J.Clin.Invest.88,1067(1991).
凝血酶是血流中的一种凝固蛋白质,其在凝固级联中具有许多作用,是凝血级联中最后的酶。它是一种丝氨酸蛋白酶,其将可溶纤维蛋白原转化成为不可溶的纤维蛋白丝,还催化许多其它的凝固相关的反应。
组织蛋白酶S,肽酶C1家族的一员,是一种溶酶体半胱氨酸蛋白酶,其可参与将抗原蛋白降解为在MHC类II分子上递呈的肽,因此它是免疫响应的关键。编码蛋白可在广泛的pH范围内作为弹性蛋白酶起作用。
材料:
●Victor3酶标仪(PerkinElmer)
●透明的96孔板(PhenixResearch)
●黑色96孔板(PerkinElmer)
●核糖核酸酶和脱氧核糖核酸酶纯水
方法:
弹性蛋白酶(人嗜中性粒细胞(Cat#16-14-051200AthensResearchandTechnology,AthensGA)):反应以每孔100μL的样品体积在透明的96孔板中进行。制成包含200mMTris-HCl(pH7.5)、150mMNaCl和50%丙三醇的2X测定缓冲液。对于每个样品,将50μL2X测定缓冲液添加至每个孔中。添加底物(MeOSuc-AAPV-pNA,显色底物,Cat#P-213,EnzoLifeSciences,PlymouthMeeting,PA;在DMSO中的50mM原种)至1mM的最终浓度。在水中以4x的浓度添加(25μL)药物稀释物。最后,制成对于每个样品具有1μL弹性蛋白酶和22μL水的混合物并且将23μL添加至每个孔。在室温下孵育样品30min。在Victor3酶标仪上读取405nM的吸光度。一式两份地测试所有的样品。结果显示为空白调整的(无弹性蛋白酶)最大吸光度的百分比,其由无抑制剂对照给出。
纤溶酶和凝血酶(SensolyteRH110纤溶酶活性测定试剂盒和Sensolyte凝血酶活性测定试剂盒(Anaspec)):反应以每孔100μL的样品体积在黑色的96孔板中进行。遵照来自于试剂盒说明书的规程A,其中用去离子水1∶1稀释2X测定缓冲液。每个测定包括阳性对照(被稀释的酶并且无测试化合物)、抑制剂对照(包含被稀释的酶和纤溶酶抑制剂;来自于试剂盒的组分E或凝血酶抑制剂;N-α-NAPAP合成抑制剂)和底物对照(测定缓冲液和底物)。还进行媒介物和自体荧光对照。在测定缓冲液中以10x的浓度添加(10μL)药物稀释物。以0.25μg/mL(纤溶酶)和1μg/mL(凝血酶)的浓度以40μL/孔将酶添加至除了底物对照之外的所有孔。最后,将包含底物的50μL测定缓冲液添加至每个孔。添加底物至50nM(纤溶酶)或20nM(凝血酶)的最终浓度。在室温下孵育样品30min。在Victor3酶标仪上在Ex/Em=490nm/520nm读取荧光强度。一式两份地测试所有的样品。结果显示为底物对照调整的最大吸光度的百分比,其由阳性对照给出。
组织蛋白酶S(Sensolyte组织蛋白酶S活性测定试剂盒(Anaspec)):反应以每孔100μL的样品体积在黑色的96孔板中进行。遵照来自于试剂盒说明书的规程A,其中将DTT添加至测定缓冲液中以产生5μM的浓度。每个测定包括阳性对照(被稀释的酶并且无测试化合物)、抑制剂对照(包含被稀释的酶和纤溶酶抑制剂;组分E或凝血酶抑制剂;N-α-NAPAP合成抑制剂)和底物对照(测定缓冲液和底物)。还进行媒介物和自体荧光对照。在测定缓冲液中以10x的浓度添加(10μL)药物稀释物。以2.5μg/mL的浓度以40μL/孔将组织蛋白酶S添加至除了底物对照之外的所有孔。最后,将包含底物的50μL测定缓冲液添加至每个孔。添加底物至16nM的最终浓度。在室温下培养样品30min。在Victor3酶标仪上在Ex/Em=490nm/520nm读取荧光强度。一式两份地测试所有的样品。结果显示为底物对照调整的最大吸光度的百分比,其由阳性对照给出。
结果显示在下表2中:
表2
实施例9
化合物对丙型肝炎病毒NS3/4AWT和突变蛋白酶的活性
使用荧光共振能量转移(FRET)肽(AnaSpec)使用SensoLyte490HCV蛋白酶测定试剂盒进行HCVNS3/4A蛋白酶测定。
结果显示在下表3和4中:
表3
表4
虽然前述说明书教导了本发明的原理,以及为了举例说明目的提供的实施例,但是应当理解,本发明的实施包含所有的常规变化、适应性修改和/或改变,同样在所附权利要求书及其等同的范围内。
Claims (10)
1.一种式(I)的化合物:
或其药学上可接受的盐,其中
J和J1可存在或不存在,并且当存在时,独立地选自C1-C6烷基、芳基、芳烷基、烷氧基、芳氧基、酮基、羟基、氨基、芳基氨基、羧基烷基、甲酰氨基烷基、卤素、氰基、甲酰基、磺酰基或亚磺酰氨基;并且
R为C1-C10烷基,C3-C8环烷基或芳基。
2.权利要求1的化合物,其中J和J1独立地为卤素。
3.权利要求1的化合物,其中J和J1独立地为氟。
4.权利要求1的化合物,其中J和J1独立地为氟,R为叔丁基。
5.权利要求1的化合物,其结构式如下:
6.权利要求1的化合物,其中所述化合物或其药学上可接受的盐可以为单一对映体、立体异构体、旋转异构体、外消旋体或其混合物的形式。
7.权利要求1的化合物用于制备治疗或预防HCV感染或降低HCV生物活性用的药物的用途。
8.权利要求7的用途,其中所述药物进一步包含其它的抗HCV剂。
9.权利要求1的化合物用于制备抑制丝氨酸蛋白酶活性用的药物的用途。
10.权利要求7-9任一项的用途,其中所述药物进一步包含药学上合适的载体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40898910P | 2010-11-01 | 2010-11-01 | |
US61/408,989 | 2010-11-01 | ||
PCT/US2011/058404 WO2012061248A2 (en) | 2010-11-01 | 2011-10-28 | Novel specific hcv ns3 protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103328466A CN103328466A (zh) | 2013-09-25 |
CN103328466B true CN103328466B (zh) | 2016-08-03 |
Family
ID=46025037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180063866.1A Active CN103328466B (zh) | 2010-11-01 | 2011-10-28 | Hcv ns3蛋白酶抑制剂 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8729014B2 (zh) |
EP (1) | EP2635570B1 (zh) |
JP (1) | JP5828903B2 (zh) |
CN (1) | CN103328466B (zh) |
AU (1) | AU2011323658A1 (zh) |
BR (1) | BR112013010836A2 (zh) |
CA (1) | CA2815855C (zh) |
IL (1) | IL225908A0 (zh) |
MX (1) | MX2013004906A (zh) |
WO (1) | WO2012061248A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103096891A (zh) | 2010-06-24 | 2013-05-08 | 判米德有限公司 | 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病 |
CN103328466B (zh) | 2010-11-01 | 2016-08-03 | Rfs制药公司 | Hcv ns3蛋白酶抑制剂 |
WO2012176149A1 (en) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Treatment of hepatitis c virus |
CN104039774A (zh) | 2012-01-12 | 2014-09-10 | Rfs制药公司 | Hcv ns3蛋白酶抑制剂 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
RU2016144076A (ru) * | 2014-04-15 | 2018-05-16 | Кокристал Фарма, Инк. | Сильнодействующие и селективные ингибиторы вируса гепатита с |
CN105315261A (zh) * | 2014-08-04 | 2016-02-10 | 正大天晴药业集团股份有限公司 | Hcv ns3蛋白酶抑制剂的钠盐 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101189223A (zh) * | 2005-02-08 | 2008-05-28 | 布里斯托尔-迈尔斯斯奎布公司 | 丙型肝炎病毒抑制剂 |
CN101495457A (zh) * | 2006-07-05 | 2009-07-29 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995000536A1 (en) | 1993-06-22 | 1995-01-05 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds |
PL194025B1 (pl) | 1996-10-18 | 2007-04-30 | Vertex Pharma | Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
EP1425029A4 (en) | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
OA13187A (en) | 2003-07-10 | 2006-12-13 | Achillion Pharmaceuticals Inc | Substituted arylthiourea derivatives useful as inhibitors of viral replication. |
ES2336009T3 (es) | 2004-01-30 | 2010-04-07 | Medivir Ab | Inhibidores de la ns-3 serina proteasa del vhc. |
CN1984922A (zh) | 2004-05-20 | 2007-06-20 | 先灵公司 | 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸 |
WO2006111906A2 (en) | 2005-04-19 | 2006-10-26 | Philips Intellectual Property & Standards Gmbh | Illumination system comprising a red-emitting ceramic luminescence converter |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
AU2006275605B2 (en) | 2005-08-01 | 2011-01-06 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as HCV NS3 protease inhibitors |
WO2007089618A2 (en) | 2006-01-27 | 2007-08-09 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
US7635683B2 (en) | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
CN101553170B (zh) | 2006-11-24 | 2011-11-09 | 株式会社岛津制作所 | X射线透视摄影装置 |
US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
EP2224942A4 (en) * | 2007-12-05 | 2012-01-25 | Enanta Pharm Inc | FLUORATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
CN101951769B (zh) | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
AU2009249443A1 (en) | 2008-04-15 | 2009-11-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis C virus replication |
US8653025B2 (en) | 2010-01-27 | 2014-02-18 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
CN103328466B (zh) | 2010-11-01 | 2016-08-03 | Rfs制药公司 | Hcv ns3蛋白酶抑制剂 |
-
2011
- 2011-10-28 CN CN201180063866.1A patent/CN103328466B/zh active Active
- 2011-10-28 US US13/284,641 patent/US8729014B2/en not_active Expired - Fee Related
- 2011-10-28 JP JP2013537733A patent/JP5828903B2/ja active Active
- 2011-10-28 MX MX2013004906A patent/MX2013004906A/es active IP Right Grant
- 2011-10-28 AU AU2011323658A patent/AU2011323658A1/en not_active Abandoned
- 2011-10-28 BR BR112013010836A patent/BR112013010836A2/pt not_active IP Right Cessation
- 2011-10-28 WO PCT/US2011/058404 patent/WO2012061248A2/en active Application Filing
- 2011-10-28 CA CA2815855A patent/CA2815855C/en not_active Expired - Fee Related
- 2011-10-28 EP EP11838590.5A patent/EP2635570B1/en active Active
-
2013
- 2013-04-23 IL IL225908A patent/IL225908A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101189223A (zh) * | 2005-02-08 | 2008-05-28 | 布里斯托尔-迈尔斯斯奎布公司 | 丙型肝炎病毒抑制剂 |
CN101495457A (zh) * | 2006-07-05 | 2009-07-29 | 因特蒙公司 | C型肝炎病毒复制的新颖抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN103328466A (zh) | 2013-09-25 |
MX2013004906A (es) | 2013-12-06 |
JP2013542955A (ja) | 2013-11-28 |
WO2012061248A8 (en) | 2013-08-01 |
WO2012061248A3 (en) | 2012-08-02 |
CA2815855A1 (en) | 2012-05-10 |
BR112013010836A2 (pt) | 2019-09-24 |
AU2011323658A1 (en) | 2013-05-23 |
CA2815855C (en) | 2016-02-02 |
US20120129765A1 (en) | 2012-05-24 |
JP5828903B2 (ja) | 2015-12-09 |
US8729014B2 (en) | 2014-05-20 |
WO2012061248A2 (en) | 2012-05-10 |
EP2635570A2 (en) | 2013-09-11 |
IL225908A0 (en) | 2013-06-27 |
EP2635570A4 (en) | 2014-04-16 |
EP2635570B1 (en) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103328466B (zh) | Hcv ns3蛋白酶抑制剂 | |
US11207370B2 (en) | Peptidomimetics for the treatment of coronavirus and picornavirus infections | |
US11963972B2 (en) | Antiviral agents and nucleoside analogs for treatment of Zika virus | |
CN104039774A (zh) | Hcv ns3蛋白酶抑制剂 | |
TWI480272B (zh) | 藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法 | |
US10011629B2 (en) | Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
JP2020534361A (ja) | 置換ヌクレオシド、ヌクレオチド、及びそのアナログ | |
US10519186B2 (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus | |
TW202202148A (zh) | 用於治療covid-19之化合物及方法 | |
CA2946867C (en) | 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
CN103687866A (zh) | 用于治疗病毒性感染的嘌呤单磷酸酯前药 | |
CA3214726A1 (en) | Nucleosides and nucleotides analogs as antiviral agents | |
US20170334941A1 (en) | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
US20230322837A1 (en) | Preparation method for and application of class of stellate bifunctional compounds targeting spike protein against respiratory tract infection virus and salt thereof | |
CN106661004A (zh) | 丙型肝炎病毒的有效和选择性抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130925 Assignee: Biolinerx Ltd Assignor: RFS pharmaceutical company|Jin Nuo Sai Si pharmaceutical company Contract record no.: 2014990000851 Denomination of invention: Macrocyclic compounds as hcv ns3 protease inhibitors License type: Exclusive License Record date: 20141104 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |